Time-lapse Monitoring of Early Embryo Development After Ovarian Stimulation During Infertility Treatment

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01882166

Enrollment

Registered

2013-06-20

Start date

2013-10-31

Completion date

2015-01-01

Last updated

2018-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female

Keywords

Fertilization in Vitro, Sperm Injections, Intracytoplasmic, Follicle Stimulating Hormone, Embryonic Development

Brief summary

The number of children conceived by assisted reproductive technology is increasing in Nordic countries as well as worldwide. An important factor of success in treatment of infertility is a short time to pregnancy with impact on both economical aspects for the society and medical and psychological aspects for the couple. During treatment, success relies on 1) optimal stimulation of growth and maturation of multiple follicles by administration of exogenous follicle stimulating hormone (FSH), and 2) selection of the fertilized egg / embryo with the highest potential of implantation to be transferred to the mother. In the present project stimulation of egg production by human urine derived FSH (Fostimon®) and recombinant FSH (Puregon®) will be compared. To this end early embryo development and kinetics after fertilization will be evaluated. The system to be used is time-lapse recording of embryo morphology during the first days of embryo development by means of an embryoscope. Aim of this study is to investigate if Puregon and urinary Fostimon have different effect on embryo quality. The hypothesis of the study is that stimulation of egg production by these two types of follicle stimulating hormone does not have the same effect on early embryo quality.

Interventions

DRUGfostimon

DRUGpuregon

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 38 Years

Healthy volunteers

Inclusion criteria

* First or second intracytoplasmic sperm injection (ICSI) treatment * BMI 18-32 kg/m² * No previous ovarian hyperstimulation syndrome (OHSS) * Regular menstrual cycle (cycle length 28 ± 3 days * Less than 20 antral follicles evaluated by vaginal ultrasound * S- Anti-Müller Hormone (AMH) 10 - 40 pmol/L * has given informed consent

Design outcomes

Primary

Measure	Time frame	Description
Embryo quality	2 days	time-lapse recordings for all embryos will be evaluated by use of the EmbryoViewer (software developed for the EmbryoScope)

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026